Literature DB >> 31967000

TESTOTOXICOSIS WITH AN EPISODIC COURSE: AN UNUSUAL CASE WITHIN A SERIES.

Zeina M Nabhan, Erica A Eugster.   

Abstract

OBJECTIVE: To describe an unusual case of familial male precocious puberty (FMPP) characterized by periodic remission compared to a series of boys with typical testotoxicosis.
METHODS: Medical records of boys with FMPP followed at our institution from 2001-2017 were reviewed. Variables analyzed included age, family history, physical exam, hormone levels, bone age, and treatment.
RESULTS: A boy of age 2 years 10 months presented with growth acceleration and masturbatory behaviors. On exam, he had 6-mL testes, an enlarged phallus (10.5 × 2.5 cm), and Tanner 2 pubic hair. Testosterone was 242 ng/dL (normal level, ≤30 ng/dL). Genetic testing revealed an Asp578Gly luteinizing hormone receptor mutation confirming FMPP. Anastrozole 1 mg and bicalutamide 50 mg daily were started. During 7.5 years of follow-up, two periods of spontaneous remission occurred lasting >3 years and 10 months, respectively. Both were characterized by prepubertal testosterone levels (10 to 28 ng/dL) and arrested pubertal development off therapy. Relapses were marked by elevated testosterone, growth acceleration, and pubertal progression. Ten additional boys aged 3.46 ± 0.72 years with FMPP were identified, one of whom also had an Asp578Gly mutation. Average testosterone at presentation was 335 ± 193 ng/dL (range, 146 to 778 ng/dL) and average bone age/chronologic age was 2.02 ± 0.47. All were treated with bicalutamide and anastrozole or letrozole.
CONCLUSION: We report a case of intermittent FMPP in contrast to a series of boys with a characteristic clinical course. To our knowledge, a similar case has not previously been reported. Our case expands the clinical spectrum of this rare condition.
Copyright © 2019 AACE.

Entities:  

Year:  2019        PMID: 31967000      PMCID: PMC6876971          DOI: 10.4158/ACCR-2018-0246

Source DB:  PubMed          Journal:  AACE Clin Case Rep        ISSN: 2376-0605


  10 in total

1.  Variable presentation of precocious puberty associated with the D564G mutation of the LHCGR gene in children with testotoxicosis.

Authors:  George S Jeha; Elizabeth D Lowenthal; Wai-Yee Chan; Shao-Ming Wu; Lefkothea P Karaviti
Journal:  J Pediatr       Date:  2006-08       Impact factor: 4.406

2.  Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole.

Authors:  Nerissa C Kreher; Ora Hirsch Pescovitz; Paul Delameter; Anatoly Tiulpakov; Ze'ev Hochberg
Journal:  J Pediatr       Date:  2006-09       Impact factor: 4.406

3.  A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty.

Authors:  A Shenker; L Laue; S Kosugi; J J Merendino; T Minegishi; G B Cutler
Journal:  Nature       Date:  1993-10-14       Impact factor: 49.962

4.  Effect of Antiandrogen, Aromatase Inhibitor, and Gonadotropin-releasing Hormone Analog on Adult Height in Familial Male Precocious Puberty.

Authors:  Ellen Werber Leschek; Armando C Flor; Joy C Bryant; Janet V Jones; Kevin M Barnes; Gordon B Cutler
Journal:  J Pediatr       Date:  2017-11       Impact factor: 4.406

5.  Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT).

Authors:  Edward O Reiter; Nelly Mauras; Ken McCormick; Bindu Kulshreshtha; James Amrhein; Francesco De Luca; Sandra O'Brien; Jon Armstrong; Helena Melezinkova
Journal:  J Pediatr Endocrinol Metab       Date:  2010-10       Impact factor: 1.634

6.  Bicalutamide and third-generation aromatase inhibitors in testotoxicosis.

Authors:  Anne M Lenz; Dorothy Shulman; Erica A Eugster; Samar Rahhal; John S Fuqua; Ora H Pescovitz; Katherine A Lewis
Journal:  Pediatrics       Date:  2010-08-16       Impact factor: 7.124

7.  Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty.

Authors:  L Laue; W Y Chan; A J Hsueh; M Kudo; S Y Hsu; S M Wu; L Blomberg; G B Cutler
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

8.  Gonadotropin-independent familial sexual precocity with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent luteinizing hormone-releasing factor agonist and medroxyprogesterone acetate therapy in four cases.

Authors:  S M Rosenthal; M M Grumbach; S L Kaplan
Journal:  J Clin Endocrinol Metab       Date:  1983-09       Impact factor: 5.958

9.  Testicular leydig cell hyperplasia as a cause of familial sexual precocity.

Authors:  H K Schedewie; E O Reiter; I Z Beitins; S Seyed; V D Wooten; J F Jimenez; E J Aiman; G W DeVane; J F Redman; M J Elders
Journal:  J Clin Endocrinol Metab       Date:  1981-02       Impact factor: 5.958

10.  Rapid GDP release from Gs alpha in patients with gain and loss of endocrine function.

Authors:  T Iiri; P Herzmark; J M Nakamoto; C van Dop; H R Bourne
Journal:  Nature       Date:  1994-09-08       Impact factor: 49.962

  10 in total
  1 in total

1.  Long-Term Treatment With Letrozole in a Boy With Familial Male-Limited Precocious Puberty.

Authors:  Xin Yuan; Ruimin Chen; Ying Zhang; Xiaohong Yang; Xiangquan Lin
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-14       Impact factor: 6.055

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.